QC
RARE icon

Quadrature Capital’s Ultragenyx Pharmaceutical RARE Stock Holding History

Quadrature Capital’s Portfolio RARE Stock Details RARE Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		$1.19M Sell
56,590
-9,411
-14% -$212K 0.01% 514
2025
Q4 		$1.52M Buy
+66,001
New +$2.17M 0.02% 418
2025
Q3 		– Sell
-13,944
Closed -$507K – 1417
2025
Q2 		$507K Buy
+13,944
New +$503K 0.01% 570

Other funds holding RARE

BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
VPM
Vanguard Portfolio Management Malvern, Pennsylvania $1.91T AUM
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
AQR Capital Management
AQR Capital Management Greenwich, Connecticut $218B AUM 29.41% 1-Year Est. Return
VCM
Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM
RI
RTW Investments New York $10B AUM 135.35% 1-Year Est. Return
Sands Capital Management
Sands Capital Management Arlington, Virginia $25.5B AUM 26.46% 1-Year Est. Return
SI
Sofinnova Investments Menlo Park, California $2.63B AUM 117.41% 1-Year Est. Return
Wellington Management Group
Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return
BG
Bellevue Group Kuesnacht, Switzerland $4.2B AUM 54.85% 1-Year Est. Return

Quadrature Capital's RARE Position: Q1 2026 in Review

Quadrature Capital reduced its Ultragenyx Pharmaceutical (RARE) stake by 14% in Q1 2026, selling an estimated $212K and leaving 56,590 shares worth $1.19M. The position accounts for 0.01% of the portfolio, ranked #514.

Quadrature Capital first reported a position in RARE in Q2 2025 and has held it in 3 quarters since. The position peaked at $1.52M in Q4 2025. 295 funds tracked by Wall St. Rank hold RARE as of Q1 2026.

  • Quadrature Capital held 56,590 shares of Ultragenyx Pharmaceutical worth $1.19M as of Q1 2026.
  • Quadrature Capital sold 9,411 Ultragenyx Pharmaceutical shares in Q1 2026, an estimated $212K.
  • Ultragenyx Pharmaceutical made up 0.01% of Quadrature Capital's portfolio in Q1 2026, its #514 holding.
  • Quadrature Capital first reported a position in Ultragenyx Pharmaceutical in Q2 2025 and has held it in 3 quarters since.
  • Quadrature Capital's Ultragenyx Pharmaceutical position peaked at $1.52M in Q4 2025.
  • 295 funds tracked by Wall St. Rank held Ultragenyx Pharmaceutical as of Q1 2026.

Based on Quadrature Capital's 13F filing for Q1 2026, filed 15 May 2026.